A novel method for direct measurement of complement convertases activity in human serum

Clinical and Experimental Immunology

Volumn 178, Issue 1, 2014, Pages 142-153

  Blom, A M ^a   Volokhina, E B ^b   Fransson, V ^a   Stromberg P ^c   Berghard, L ^c   Viktorelius, M ^a   Mollnes, T E ^d,e,f   Lopez Trascasa M ^g,h   van den Heuvel, L P ^b,i   Goodship, T H ^j   Marchbank, K J ^k   Okroj, M ^a  

^a LUND UNIVERSITY   (Sweden)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c BIOVITRUM AB   (Sweden)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e NLSH   (Norway)

^f UNIVERSITY OF TROMSØ   (Norway)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j NEWCASTLE UNIVERSITY   (United Kingdom)

^k NEWCASTLE UNIVERSITY   (United Kingdom)

more..

Author keywords

Complement system; Convertase; Eculizumab; OmCI

Indexed keywords

COMPLEMENT; COMPLEMENT CONVERTASE; ECULIZUMAB; UNCLASSIFIED DRUG; AUTOANTIBODY; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; NEPHRITIC FACTOR;

ARTICLE; BLOOD SAMPLING; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT BLOOD LEVEL; HALF LIFE TIME; HEMOLYSIS; HUMAN; IMMUNOASSAY; MEASUREMENT; SCREENING; SHEEP ERYTHROCYTE; ANIMAL; ENZYMOLOGY; ERYTHROCYTE; GUINEA PIG; IMMUNOLOGY; PROCEDURES; RABBIT; SHEEP;

ANIMALS; AUTOANTIBODIES; COMPLEMENT C3 NEPHRITIC FACTOR; COMPLEMENT C3-C5 CONVERTASES; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT SYSTEM PROTEINS; ERYTHROCYTES; GUINEA PIGS; HALF-LIFE; HUMANS; IMMUNOASSAY; RABBITS; SHEEP;

EID: 84908212932     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12388     Document Type: Article

References (41)

1. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11:785-97.
2. Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol 2013; 190:3831-8.
3. Martinez-Barricarte R, Heurich M, Valdes-Canedo F et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 2010; 120:3702-12.
4. Sethi S, Fervenza FC, Zhang Y et al. Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int 2013; 83:293-9.
5. Heurich M, Martinez-Barricarte R, Francis NJ et al. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci USA 2011; 108:8761-6.
6. Warwicker P, Goodship TH, Donne RL et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998; 53:836-44.
7. Daha MR, van Es LA. Relative resistance of the F-42-stabilized classical pathway C3 convertase to inactivation by C4-binding protein. J Immunol 1980; 125:2051-4.
8. de Cordoba SR, Tortajada A, Harris CL, Morgan BP. Complement dysregulation and disease: from genes and proteins to diagnostics and drugs. Immunobiology 2012; 217:1034-46.
9. Amornsiripanitch N, Hong S, Campa MJ, Frank MM, Gottlin EB, Patz EF, Jr. Complement factor H autoantibodies are associated with early stage NSCLC. Clin Cancer Res 2010; 16:3226-31.
10. Paixao-Cavalcante D, Lopez-Trascasa M, Skattum L et al. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney Int 2012; 82:1084-92.
11. Rother U. A new screening test for C3 nephritis factor based on a stable cell bound convertase on sheep erythrocytes. J Immunol Methods 1982; 51:101-7.
12. West CD. A hemolytic method for the measurement of nephritic factor. J Immunol Methods 2008; 335:1-7.
13. Okroj M, Holmquist E, King BC, Blom AM. Functional analyses of complement convertases using C3 and C5-depleted sera. PLOS ONE 2012; 7:e47245.
14. Nunn MA, Sharma A, Paesen GC et al. Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata. J Immunol 2005; 174:2084-91.
15. Kaplan M. Eculizumab (Alexion). Curr Opin Investig Drugs 2002; 3:1017-23.
16. Jokiranta TS, Zipfel PF, Hakulinen J et al. Analysis of the recognition mechanism of the alternative pathway of complement by monoclonal anti-factor H antibodies: evidence for multiple interactions between H and surface bound C3b. FEBS Lett 1996; 393:297-302.
17. Oppermann M, Manuelian T, Jozsi M et al. The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein. Clin Exp Immunol 2006; 144:342-52.
18. Dahlbäck B, Hildebrand B, Malm J. Characterization of functionally important domains in human vitamin K-dependent protein S using monoclonal antibodies. J Biol Chem 1990; 265:8127-35.
19. Okroj M,Mark L, Stokowska A et al. Characterization of the complement inhibitory function of rhesus rhadinovirus complement control protein (RCP). J Biol Chem 2009; 284:505-14.
20. Dragon-Durey MA, Loirat C, Cloarec S et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16:555-63.
21. Moore I, Strain L, Pappworth I et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010; 115:379-87.
22. Watson R, Lindner S, Bordereau P et al. Standardisation of the factor H autoantibody assay. Immunobiology 2014; 219:9-16.
23. Forsgren A, Quie PG. Influence of the alternate complement pathway in opsonization of several bacterial species. Infect Immun 1974; 10:402-4.
24. Medof ME, Kinoshita T, Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 1984; 160:1558-78.
25. Lublin DM, Atkinson JP. Decay-accelerating factor: biochemistry, molecular biology, and function. Ann Rev Immunol 1989; 7:35-58.
26. Servais A, Noel LH, Fremeaux-Bacchi V, Lesavre P. C3 glomerulopathy. Contrib Nephrol 2013; 181:185-93.
27. Volokhina E, Westra D, Xue X, Gros P, van de Kar N, van den Heuvel L. Novel C3 mutation p.Lys65Gln in aHUS affects complement factor H binding. Pediatr Nephrol 2012; 27:1519-24.
28. Lehtinen MJ, Rops AL, Isenman DE, van der Vlag J, Jokiranta TS. Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome. J Biol Chem 2009; 284:15650-8.
29. Roumenina LT, Frimat M, Miller EC et al. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood 2012; 119:4182-91.
30. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J et al. Gainof-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA 2007; 104:240-5.
31. Sahu A, Kay BK, Lambris JD. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J Immunol 1996; 157:884-91.
32. Dragon-Durey MA, Blanc C, Marinozzi MC, van Schaarenburg RA, Trouw LA. Autoantibodies against complement components and functional consequences. Mol Immunol 2013; 56:213-21.
33. Van Dijk H, Rademaker PM, Willers JM. Determination of alternative pathway of complement activity in mouse serum using rabbit erythrocytes. J Immunol Methods 1980; 36:29-39.
34. Ferreira VP, Pangburn MK, Cortes C. Complement control protein factor H: the good, the bad, and the inadequate. Mol Immunol 2010; 47:2187-97.
35. Sanchez-Corral P, Gonzalez-Rubio C, Rodriguez de Cordoba S, Lopez-Trascasa M. Functional analysis in serum from atypical hemolytic uremic syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol Immunol 2004; 41:81-4.
36. Ferreira VP, Pangburn MK. Factor H mediated cell surface protection from complement is critical for the survival of PNH erythrocytes. Blood 2007; 110:2190-2.
37. Horl S, Banki Z, Huber G et al. Reduction of complement factor H binding to CLL cells improves the induction of rituximabmediated complement-dependent cytotoxicity. Leukemia 2013; 27:2200-8.
38. Okroj M, Eriksson I, Osterborg A, Blom AM. Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement. Med Oncol 2013; 30:759.
39. Jelezarova E, Schlumberger M, Sadallah S, Spath PJ, Schifferli JA, Lutz HU. A C3 convertase assay for nephritic factor functional activity. J Immunol Methods 2001; 251:45-52.
40. Pangburn MK, Muller-Eberhard HJ. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells. Proc Natl Acad Sci USA 1978; 75:2416-20.
41. Bergseth G, Ludviksen JK, Kirschfink M, Giclas PC, Nilsson B, Mollnes TE. An international serum standard for application in assays to detect human complement activation products. Mol Immunol 2013; 56:232-9.